Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Lung 8
2011-002380-24Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Pulmonary squamous cell carcinoma comparing Afatinib with Erlotinib (2 arms). Primary endpoint: Progression-free survival. Started Dec 2011; status: completed.
02
Drugs
afatiniberlotinib
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2011-002380-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002380-24.